Skip to content
Biodatica
Start free

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

Zhengzhou, Henan

OncologyGrant-only
Compare Sign in to watch

What changed

Phase I trial registered: Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

12mo agoTrial registeredJul 20, 2025Source filing (opens the source filing in a new tab)

Momentum

46no change

Momentum 46 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,080 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Nov 21, 2024

    Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, Prostate Cancer, BRCA Mutation, HRR Deficiency · RECRUITING · sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06666270 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources